基于网络药理学探讨芪莲益肾膏治疗慢性肾脏病的免疫调节机制

Abstract
Figure/Table
References (27)
Related Citation (15)

Download: PDF (1550 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the immune regulatory mechanism of Qilian Yishen Ointment in the treatment of chronic kidney disease based on network pharmacology. Methods The active ingredients and corresponding targets of Qilian Yishen Ointment were searched through traditional Chinese medicine systems pharmacology database and analysis platform. The target information was standardized by DrugBank database and UniProt database. The targets related to chronic kidney disease were searched by DrugBank, TTD, CTD, and GeneCards database. The potential targets of overlap between Qilian Yishen Ointment and chronic kidney disease were obtained. Cytoscape 3.2.1 was used to construct the component-target network diagram, and DAVID database was used to analyze the GO biological process and KEGG signal pathway enrichment. Through literature review, the immune-related pathway of Qilian Yishen Ointment in the treatment of chronic kidney disease was obtained, and the results were verified by molecular docking technology. Results A total of 144 candidate active ingredients and 261 targets were screened from Qilian Yishen Ointment, among which 83 targets overlaps with those related to chronic kidney disease. The main components of Qilian Yishen Ointment in the treatment of chronic kidney disease were balletin, luteolin, kaempiol, etc. The pathways related to immune regulation mainly involve IL-17, TNF, Th17 cell differentiation, NF-κB, JAK-STAT, and other signaling pathways. Molecular docking preliminarily verified that the main active ingredients could bind Foxp3 and RORγt to play biological roles. Conclusion This study preliminarily reveals the immune regulatory mechanism of Qilian Yishen Ointment with multiple components, multiple targets and multiple approaches in the treatment of chronic kidney disease, and provides a basis for the clinical development and utilization of Qilian Yishen Ointment.

Key words： Qilian Yishen ointment Chronic kidney disease Immune regulatory Network pharmacology Molecular docking Signaling pathways

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Yanfang1 SHI Hongshuo1 ZHANG Yingying1 YANG Tiantian1
	2 SI Guomin1
	2

Cite this article:

WANG Yanfang1 SHI Hongshuo1 ZHANG Yingying1 YANG Tiantian1,2 SI Guomin1,2. Discussion on the immune regulatory mechanism of Qilian Yishen Ointment in the treatment of chronic kidney disease based on network pharmacology#br#[J]. 中国医药导报, 2021, 18(30): 14-18.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I30/14

[1] 张承华.益肾健脾和络泄浊法治疗CKD3-5期疗效的回顾性分析及核心方网络药理学研究[D].南京：南京中医药大学，2020.
[2] GBD Chronic Kidney Disease Collaboration. Global，regional，and national burden of chronic kidney disease，1990- 2017： a systematic analysis for the Global Burden of Disease Study 2017 [J]. Lancet，2020，395（10225）：709-733.
[3] 高然.参芪解毒膏治疗脾肾虚衰、浊毒潴留型慢性肾衰早中期的临床疗效观察[D].济南：山东中医药大学，2016.
[4] Qi F，Cai P，Liu X，et al. Adenovirus-mediated P311 inhibits TGF-beta1-induced epithelial-mesenchymal transition in NRK-52E cells via TGF-beta1-Smad-ILK pathway [J]. Biosci Trends，2015，9（5）：299-306.
[5] Qi FH，Cai PP，Liu X，et al. Adenovirus-mediated P311 ameliorates renal fibrosis through inhibition of epithelial-mesenchymal transition via TGF-beta1-Smad-ILK pathway in unilateral ureteral obstruction rats [J]. Int J Mol Med，2018，41（5）：3015-3023.
[6] 高然，刘荣，司国民.参芪解毒汤联合P311在肾间质纤维化过程中对α-SMA及α-SMA2mRNA表达的影响[J].世界中西医结合杂志，2016，11（1）：41-43.
[7] Cai P，Liu X，Xu Y，et al. Shenqi detoxification granule combined with P311 inhibits epithelial-mesenchymal transition in renal fibrosis via TGF-beta1-Smad-ILK pathway [J]. Biosci Trends，2017，11（6）：640-650.
[8] 马秋波，包宇实. 慢性肾脏病肾间质纤维化免疫机制研究进展[J].中华实用诊断与治疗杂志，2018，32（1）：101-104.
[9] 曹灿，崔瑛，楚玉玺，等.基于网络药理学与分子对接方法的疏风解毒胶囊治疗新型冠状病毒肺炎（COVID-19）的作用机制与活性成分研究[J].中草药，2020，51（9）：2283-2296.
[10] 刘夫艳，唐德才，谭喜莹.黄芪-莪术药对基于网络药理学的抗大肠癌分子机制[J].中国实验方剂学杂志，2019， 25（13）：176-185.
[11] 余平，郑建红，楼婷婷.基于网络药理学六君子汤治疗胃癌的物质基础与作用机制研究[J].中国现代应用药学，2019，36（12）：1508-1515.
[12] 范荣荣，罗子清，唐丽娟，等.基于网络药理学的小青龙汤治疗支气管哮喘作用机制分析[J].中药新药与临床药理，2019，30（1）：52-59.
[13] 陈芝强，陈怡，麦喆钘，等.基于网络药理学探讨二至丸治疗肝细胞癌的作用机制[J].中国实验方剂学杂志，2020，26（3）：166-174.
[14] 张友刚，李昊楠，史永平，等.基于网络药理学研究脑血疏口服液治疗脑出血的作用机制[J].中成药，2021，43（1）：234-240.
[15] 赵萌.伏邪理论指导下的慢性肾脏病的临床研究[D].北京：北京中医药大学，2018.
[16] 郑艳.肾衰方及其拆方对慢性肾衰竭模型大鼠微炎症状态影响的实验研究[D].沈阳：辽宁中医药大学，2019.
[17] Schomig M，Eisenhardt A，Ritz E. The microinflammatory state of uremia [J]. Blood Purif，2000，18（4）：327-332.
[18] 胡军福.健脾益肾、活血泄浊法对CKD4期（脾肾气虚、瘀浊内阻型）患者微炎症状态的影响[D].南宁：广西中医药大学，2019.
[19] Zhu X，Li S，Zhang Q，et al. Correlation of increased Th17/Treg cell ratio with endoplasmic reticulum stress in chronic kidney disease [J]. Medicine（Baltimore），2018， 97（20）：e10748.
[20] 王震宇，高超，邢秀玲，等.健脾补肾、益气祛浊法治疗糖尿病肾病Ⅲ期的疗效观察及对免疫功能的影响[J].天津中医药大学学报，2021，40（1）：46-50.
[21] 黄秀丽，吴艳，喻荷淋，等米沙坦联合前列地尔对糖尿病肾病氧化应激、免疫炎性反应及肾功能的影响[J].疑难病杂志，2020，19（7）：705-708，713.
[22] 周元君，金兆辰.中晚期慢性肾脏病患者血脂异常及其与微炎症状态的相关性[J].包头医学院学报，2019，35（8）：1-8.
[23] 何吉芬，陈苹，李文玮，等.复方血栓通胶囊对早期糖尿病肾病患者局部血流及微炎症反应的影响观察[J].中国医药科学，2021，11（5）：19-23.
[24] Zhang H，Yin L，Lu M，et al. Evodiamine attenuates adjuvant-induced arthritis in rats by inhibiting synovial inflammation and restoring the Th17/Treg balance [J]. J Pharm Pharmacol，2020，72（6）：798-806
[25] 章志琴.瑞香素对RSA模型小鼠Th17/Treg失衡的免疫调节机制研究[D].南昌：南昌大学，2020.
[26] Schraml BU，Hildner K，Ise W，et al. The AP-1 transcription factor Batf controls T（H）17 differentiation [J]. Nature，2009，460（7253）：405-409.
[27] Zhou L，Littman DR. Transcriptional regulatory networks in Th17 cell differentiation [J]. Curr Opin Immunol，2009， 21（2）：146-152.